PMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ProMIS Neurosciences Inc (PMN) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company faces significant financial challenges, including negative earnings and a recent net loss. Despite the pre-market price increase, technical indicators and lack of positive trading signals do not support a strong entry point. Additionally, there are no significant positive catalysts or influential trades to justify a buy decision at this time.
The MACD histogram is negative and expanding, indicating bearish momentum. The RSI is neutral at 23.767, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level (S1: 14.981), with resistance levels at R1: 20.24 and R2: 21.864.
The company has initiated the PRECISE-AD Phase 1b clinical trial in Alzheimer's patients, which could be a long-term positive if successful.
The company reported a significant net loss of $39.72 million for FY2025 and has a weak cash position of $6.1 million. Additionally, the EPS missed expectations, and the company is raising up to $200 million through securities offerings, which could dilute shareholder value.
The company's financial performance in FY2025 was poor, with a net income drop of -224.84% YoY and EPS down -176.91% YoY. Revenue remains at 0, with no growth.
No analyst rating or price target changes available.
